Taysha Gene Therapies (TSHA) Misses Q3 EPS by 27c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($1.35), $0.27 worse than the analyst estimate of ($1.08).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
• AeroVironment restates quarterly financials, citing $89M goodwill error
• MP Materials seen largely insulated after China export-control move